Andrea Montes-Torres1*, Celia Camarero-Mulas2
Andrea Montes-Torres1*, and Celia Camarero-Mulas2
1Department of Dermatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
2Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
*Corresponding Author: Andrea Montes-Torres, Department of Dermatology, Hospital Clinico Universitario Lozano Blesa, Avda, de San Juan Bosco, 15, 50009 Zaragoza, Spain, Tel: +34-91-5202433; Fax: +34-91-5202435; E-mail: firstname.lastname@example.org.
Received Date: January 02, 2021
Published Date: March 02, 2021
Copyright: Montes-Torres A, et al. ©2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation: Montes-Torres A, et al. Severe Acneiform Eruption Secondary to Cetuximab Successfully Treated with Isotretinoin. M J Derm. 05(1):15.
Acneiform reactions are one of the most common and earliest cutaneous side-effects associated with the use of epidermal growth factor receptor (EGFR) inhibitors, widely used in the management of advanced-stage solid tumors such as cetuximab and panitumumab (anti-EGFR monoclonal antibodies), anderlotinib and gefitinib (EGFR tyrosine kinase inhibitors).